Tag: Silo Pharma - Psilocybin Alpha

New Resource: Psychedelic Legalization & Decriminalization Tracker

Silo Pharma Advances Psychedelic Patent Portfolio

Silo Pharma Advances Psychedelic Patent Portfolio

Post published:August 25, 2021
Post category:Press Release

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Post published:July 27, 2021
Post category:Press Release

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Post published:July 12, 2021
Post category:Press Release

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Post published:June 8, 2021
Post category:Press Release

Silo Pharma Submits Application for NASDAQ up-listing

Silo Pharma Submits Application for NASDAQ up-listing

Post published:May 25, 2021
Post category:Press Release

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Post published:May 13, 2021
Post category:Press Release

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

Post published:April 28, 2021
Post category:Press Release

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Post published:April 22, 2021
Post category:Press Release

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Post published:April 7, 2021
Post category:Press Release

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Post published:March 4, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.